Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00052949 |
Recruitment Status
:
Completed
First Posted
: January 27, 2003
Last Update Posted
: October 8, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Recurrent Small Cell Lung Cancer | Drug: imatinib mesylate Other: laboratory biomarker analysis | Phase 2 |
PRIMARY OBJECTIVES:
I. Determine the response rate, time to progression, and overall survival of patients with recurrent small cell lung cancer treated with imatinib mesylate.
II. Correlate the presence of c-Kit mutations in tumor tissue with treatment response in patients treated with this drug.
III. Correlate individual patient variation in clinical (toxicity and/or activity), pharmacologic (pharmacokinetic/pharmacodynamic parameters), and/or biologic (correlative laboratory study results) responses to this drug with genetic differences in proteins involved in drug response (transport, metabolism, and/or mechanism of action).
OUTLINE: This is a multicenter study. Patients are stratified according to length of prior therapy (less than 3 months vs at least 3 months).
Patients receive oral imatinib mesylate twice daily for 28 days. Courses continue in the absence of disease progression or unacceptable toxicity.
*Patients are followed every 3 months until disease progression and then every 6 months for up to 3 years after registration.
NOTE: *Patients who develop CNS metastasis as the only site of disease progression receive therapeutic whole-brain radiotherapy and then resume study therapy.
PROJECTED ACCRUAL: A total of 41 patients for stratum I will be accrued within 21 months and 50 patients for stratum II will be accrued within 25 months for this study.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 91 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Trial of STI571 in Patients With Relapsed Small Cell Lung Cancer |
Study Start Date : | May 2003 |
Actual Primary Completion Date : | October 2007 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (imatinib mesylate)
Patients receive oral imatinib mesylate twice daily for 28 days. Courses continue in the absence of disease progression or unacceptable toxicity.
|
Drug: imatinib mesylate
Given orally
Other: laboratory biomarker analysis
Correlative studies
|
- The proportion of patients progression-free [ Time Frame: 16 weeks ]Ninety-five percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.
- Survival time [ Time Frame: From registration to death due to any cause, assessed up to 3 years ]Estimated using the method of Kaplan-Meier.
- Time to disease progression [ Time Frame: From randomization to documentation of disease progression, assessed up to 3 years ]Estimated using the method of Kaplan-Meier.
- Duration of response (complete response [CR] or partial response [PR]) [ Time Frame: The date from which the patient's objective status if first noted to be either a CR or PR to the date progression is documented, assessed up to 3 years ]
- Time to treatment failure [ Time Frame: From the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, refusal, or death, assessed up to 3 years ]
- Toxicity defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment, per the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 2.0 [ Time Frame: Up to 3 years ]The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Histologically or cytologically confirmed small cell lung cancer (SCLC)
- No mixed histology
- Must have received only 1 prior treatment regimen (e.g., cyclophosphamide, doxorubicin, and vincristine alternating with etoposide and cisplatin allowed)
- c-Kit positive by immunohistochemistry (at least 1+)
-
At least 1 unidimensionally measurable lesion
- Longest diameter at least 20 mm
-
No uncontrolled CNS metastasis
- Treated CNS metastasis allowed
- Performance status - ECOG 0-2
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 9 g/dL
- Total bilirubin no greater than 1.5 times upper limit of normal (ULN)
- Direct bilirubin no greater than ULN
- Creatinine no greater than 1.5 times ULN
- No unstable angina pectoris
- No uncontrolled congestive heart failure within the past 3 months unless ejection fraction is greater than 40%
- No myocardial infarction within the past 3 months
- No uncontrolled infection
- No other malignancy within the past 3 years except skin cancer or localized prostate cancer
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for at least 3 months after study participation
- See Disease Characteristics
- More than 3 weeks since prior chemotherapy
- More than 2 weeks since prior radiotherapy
-
No concurrent radiotherapy(including palliative therapy for bone pain)
- Concurrent whole-brain radiotherapy for CNS progression allowed
- More than 3 weeks since prior major surgery
- No prior imatinib mesylate

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00052949
United States, Minnesota | |
North Central Cancer Treatment Group | |
Rochester, Minnesota, United States, 55905 |
Principal Investigator: | Alex Adjei | North Central Cancer Treatment Group |
Responsible Party: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00052949 History of Changes |
Other Study ID Numbers: |
NCI-2012-01801 NCI-2012-01801 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) CDR0000269156 NCCTG-N0124 CALGB-30201 N0124 ( Other Identifier: North Central Cancer Treatment Group ) N0124 ( Other Identifier: CTEP ) U10CA025224 ( U.S. NIH Grant/Contract ) |
First Posted: | January 27, 2003 Key Record Dates |
Last Update Posted: | October 8, 2013 |
Last Verified: | October 2013 |
Additional relevant MeSH terms:
Lung Neoplasms Small Cell Lung Carcinoma Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
Carcinoma, Bronchogenic Bronchial Neoplasms Imatinib Mesylate Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |